Evaluation of Anxiety Levels in Patients Undergoing Intravitreal Injection for Diabetic Macular Edema

Year 2024, Volume: 7 Issue: 2, 90 - 93, 30.06.2024

Gonca Ayşe Ünal , Ayşegül Barak , Emin Serbülent Güçlü , Pınar Eröz , Levent Doğan , Ömer Özer

https://doi.org/10.36516/jocass.1454501

Abstract

Objective: In this study, we aimed to analyze the anxiety levels of patients regarding intravitreal injection (IVI) using the Amsterdam Preoperative Anxiety and Information Scale (APAIS) and to evaluate the effect of repeated injections on anxiety levels.
Methods: Between September 01, 2023 and January 10, 2024, 85 patients who underwent intravitreal anti-vascular endothelial growth factor injection for diabetic macular edema in our clinic were included in this study.
Results: According to APAIS scores, mean anesthesia anxiety was 5.4±2.6, surgical anxiety was 5.1±2.6 and total anxiety score was 10.5±3.7. Anesthesia information need was 2.7±0.95, surgical information need was 2.6±1.14 and total information need score was 5.3±1.50. There was no significant difference between genders in terms of total and subgroup scores (p>0.05, all). No significant correlation was found in the correlation analysis between age and number of injections and APAIS scores (subdimensions and total) (p>0.05, all).
Conclusion: In conclusion, the potential anxiety of patients before and during intravitreal injection should be considered. In addition, since IVI often involves repeated treatments, it is of great importance to identify modifiable factors that may reduce anxiety. Given the importance of compliance, premedication may be considered to reduce anxiety, especially in high-risk (high preoperative anxiety) patients. Comprehensive explanations about treatment and well-structured processes are crucial for long-term adherence to anti-VEGF therapy.

Keywords

anti-VEGF, anxiety, diabetic retinopathy, intravitreal

References

• 1.Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014 Aug 29;8(8):CD005139. https://doi.org/10.1002/14651858.CD005139.pub3
• 2.Moerman N, van Dam FS, Muller MJ, Oosting H. The Amsterdam Preoper-ative Anxiety and Information Scale (APAIS). Anesth Analg. 1996 Mar;82(3):445-51. https://doi.org/10.1213/00000539-199603000-00002
• 3.Çetinkaya F, Kavuran E, Aslan KS. Validity and Reliability of The Amster-dam Preoperative Anxiety and Information Scale in The Turkish Popula-tion. Turkish Journal Of Medical Sciences. 2019;49(1):178-83. https://doi.org/10.3906/sag-1806-84
• 4.Harris M, Lead C, Warehouse V. The NHS diabetic eye screening pro-gramme: new common pathway. London: The Royal College of Ophthal-mologists, Focus, 2012.
• 5.Lau PE, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;24:8567912 https://doi.org/10.1155/2018/8567912
• 6.Segal O, Segal-Trivitz Y, Nemet AY, Cohen P, Geffen N, Mimouni M. Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. 2016;94 (2):203-4. https://doi.org/10.1111/aos.12802
• 7.Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol. 2017 May;177:213-24. https://doi.org/10.1016/j.ajo.2017.03.005
• 8.Thetford C, Hodge S, Harding S, et al. Living with age-related macular degeneration treatment: patient experiences of being treated with ranibi-zumab (Lucentis) intravitreal injections. Br J Vis Impair 2013;31(2):89-101. https://doi.org/10.1177/0264619613481778
• 9.Kellner U, Bedar MS, Weinitz S, et al. Treatment contentment and prefer-ence of patients undergoing intravitreal anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3649-54. https://doi.org/10.1007/s00417-021-05324-8
• 10.Chen X, Seth RK, Rao VS, Huang JJ, Adelman RA. Effects of music therapy on intravitreal injections: a randomized clinical trial. J Ocul Pharmacol Ther. 2012;28(4):414-9. https://doi.org/10.1089/jop.2011.0257
• 11.Ouadfel A, El Sanharawi M, Tahiri Joutei Hassani R. Contribution of respiratory relaxation techniques during intravitreal injections: A pilot study. J Fr Ophtalmol. 2021 Jun;44(6):842-8 https://doi.org/10.1016/j.jfo.2020.09.028
• 12.Shaughnessy D, Powell S, O'Toole L. The value of handholding during intravitreal injections. Ir J Med Sci. 2023 Feb;192(1):441-5. https://doi.org/10.1007/s11845-022-02986-z
• 13.Wasser LM, Roditi E, Weiss AR, et al. Anxiety and pain perception using a speculum-free eyelid retraction technique for intravitreal injection. Graefes Arch Clin Exp Ophthalmol. 2022 Jun;260(6):2023-8. https://doi.org/10.1007/s00417-021-05422-7
• 14.Berger V, Munk MR, Lersch F, et al, Zinkernagel MS. Association of Intravitreal Injections With Blood Pressure Increase: The Following Excitement and Anxiety Response Under Intravitreal Injection Study. JAMA Ophthalmol. 2019 Jan 1;137(1):87-90. https://doi.org/10.1001/jamaophthalmol.2018.4892
• 15.Chaudhary V, Gusenbauer K, Mak M, Barbosa J, Mohammad Mohaghegh PS, Popovic M. Waiting room educational media effect on preinjection anxiety for initial intravitreal injections. Can J Ophthalmol. 2016 Apr;51(2):71-5. https://doi.org/10.1016/j.jcjo.2015.11.003